This resource center is supported by an educational grant from Gilead Sciences, Inc.

Recent advances in TROP2-directed antibody-drug conjugates (ADCs) are poised to reshape the first-line treatment landscape for metastatic triple-negative breast cancer (mTNBC). These agents are being studied both as monotherapy for immunotherapy (IO)-ineligible patients and in combination with checkpoint inhibitors for IO-eligible populations. Recently reported data from pivotal trials represents a potentially practice-changing shift in the first-line treatment landscape for both IO-eligible and -ineligible patients with mTNBC. This series of two 30-minute podcasts focuses on the efficacy and safety of TROP2-directed ADCs in mTNBC, as well as patient selection and toxicity management strategies, with emphasis on the real-world implications of recent trial data through concise, evidence-based expert discussions.

CE Activity Curriculum - Physician Credit

Resource Links

CE Activity Curriculum - Physician Credit

Resource Links

Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer – [https://pubmed.ncbi.nlm.nih.gov/41124233/]

Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer – [https://pubmed.ncbi.nlm.nih.gov/41564397/]

First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase III TROPION-Breast02 trial – [https://oncologypro.esmo.org/congress-resources/esmo-congress-2025?presentation=first_line__1l__datopotamab_deruxtecan__dato_dxd___757d4a2]

Current Frontline Treatment Approaches and Challenges in Advanced TNBC – [https://www.onclive.com/view/current-frontline-treatment-approaches-and-challenges-in-advanced-tnbc?_gl=1*168q7wf*_gcl_au*MTI2NzAyNzIxMS4xNzY4ODMxNDg0LjEzOTIyNTE4NjcuMTc3MjAzNTk2Ny4xNzcyMDM5MDEz*_ga*NzAzMjA5OTE1LjE3NTMxMDQ1NjQ.*_ga_T0X24GWRXM*czE3NzIwMzMyOTIkbzEwMSRnMSR0MTc3MjAzOTM3OSRqNjAkbDAkaDA.]

Advancing ADC Strategies in Triple-Negative Breast Cancer: Addressing Unmet Needs and Emerging Combination – [https://www.onclive.com/view/advancing-adc-strategies-in-triple-negative-breast-cancer-addressing-unmet-needs-and-emerging-combination?_gl=1*zufqac*_gcl_au*MTI2NzAyNzIxMS4xNzY4ODMxNDg0LjEzOTIyNTE4NjcuMTc3MjAzNTk2Ny4xNzcyMDM5MDEz*_ga*NzAzMjA5OTE1LjE3NTMxMDQ1NjQ.*_ga_T0X24GWRXM*czE3NzIwMzMyOTIkbzEwMSRnMSR0MTc3MjAzOTM3OSRqNjAkbDAkaDA.]

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer – [https://www.gotoper.com/courses/medical-crossfire-the-who-when-and-how-of-trop2-targeting-adcs-icis-and-parp-inhibition-in-triple-negative-breast-cancer-full]

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC – [https://www.gotoper.com/courses/expert-roundtable-and-panel-discussions-current-and-future-landscape-of-tnbc]

Establishing the Rationale for ADC and ICI Combinations in TNBC – [https://www.gotoper.com/courses/establishing-the-rationale-for-adc-and-ici-combinations-in-tnbc]

 
Nothing here yet, get started by adding a discussion.